Results 41 to 50 of about 36,304 (249)

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans [PDF]

, 2006
Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1) lowers glycaemia by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying.Aims: To assess the effects of endogenous GLP-1 on endocrine pancreatic ...
Göke, Burkhard, Katschinski, M., Nicolaus, Mathias, Roggel, R., Schirra, Joerg, Storr, Martin, Woerle, H. J.   +6 more
core   +2 more sources

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide

Сахарный диабет, 2011
The review is devoted to the pharmacological effects, the results of clinical trials, safety and the research perspectives of the first incretinomimetic ...
Alexander Sergeevich Ametov, Lyudmila Leonidovna Kamynina   +1 more
doaj   +1 more source

What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters [PDF]

, 2016
Diabetes Mellitus (DM) is a syndrome caused by various etiologies. The clinical manifestations of DM are not indicative of the cause of the disease, but might be indicative of the stage and severity of the disease process.
Abdul-Rasoul, Agarwal, Ahlgren, Alejandro, American Diabetes Association, Anderson, Appleton, Atkins, Atkins, Batchelor, Belle, Bostrom, Brackeva, Brenner, Butler, Catchpole, Catchpole, Chiang, Concannon, Coppieters, Cui, Das, Davison, Davison, Davison, De Cock, Eigenmann, Fajans, Fall, Forcada, Forcada, Forsberg, Furrer, Gepts, Gilor, Gilor, Gilor, Girman, Goossens, Gostelow, Gottlieb, Guptill, Haines, Hall, Herold, Hess, Hewson-Hughes, Hoenig, Hoenig, Hoffmann, Holst, Hume, Imamura, Jensen, Kappe, Kennedy, Kenny, Kilpatrick, Kim, Kitamura, Klupa, Kramer, Kramer, Lem, Ling, Link, Lutz, Mattin, McDonald, Miceli, Michels, Neiger, Nelson, Nelson, Niessen, Niessen, Nishii, Orban, Panciera, Papa, Pietropaolo, Porte, Porte, Prahl, Prasad, Rand, Ranta, Reaven, Russell-Jones, Safra, Scudder, Shields, Slingerland, Solanki, Strage, Sun, Temple, Thomas, Vegiopoulos, Verkest, Watson, Watson, Williams, Xenoulis, Yang, Zini, Zini, Zini, Zini, Zini, Zini   +110 more
core   +3 more sources

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects

Frontiers in Endocrinology
IntroductionIncretin-based drugs are extensively utilized in the treatment of type 2 diabetes (T2D), with remarkable clinical efficacy. These drugs were developed based on findings that the incretin effect is reduced in T2D.
Akihiro Hamasaki, Akihiro Hamasaki, Norio Harada, Atsushi Muraoka, Shunsuke Yamane, Erina Joo, Kazuyo Suzuki, Nobuya Inagaki   +7 more
doaj   +1 more source

Enteroinsular axis response to carbohydrates and fasting in healthy newborn foals

Journal of Veterinary Internal Medicine, 2019
Background The enteroinsular axis (EIA) comprises intestinal factors (incretins) that stimulate insulin release after PO ingestion of nutrients. Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are the main incretins.
Lindsey M. Rings, Jacob M. Swink, Laura K. Dunbar, Teresa A. Burns, Ramiro E. Toribio   +4 more
doaj   +1 more source

First GLP-1 analog liraglutide: the result of clinical trails on efficacy

Сахарный диабет, 2011
This review analytically considers the results of clinical trials on efficacy and safety and clinical perspectives of GLP-1 analog ...
Alexander Sergeevich Ametov, Lyudmila Leonidovna Kamynina   +1 more
doaj   +1 more source

Role of fasting duration and weekday in incretin and glucose regulation

Endocrine Connections, 2020
Fasting duration has been associated with lower fasting blood glucose levels, but higher 2-h post-load levels, and research has indicated an adverse effe ct of ‘weekend behavior’ on human metabolism.
Kim K B Clemmensen, Jonas S Quist, Dorte Vistisen, Daniel R Witte, Anna Jonsson, Oluf Pedersen, Torben Hansen, Jens J Holst, Torsten Lauritzen, Marit E Jørgensen, Signe Torekov, Kristine Færch   +11 more
doaj   +1 more source

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [PDF]

, 2016
Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of
Avogaro, Angelo, Bonora, Enzo, Fadini, GIAN PAOLO, Prato, Stefano Del, Sesti, Giorgio   +4 more
core   +3 more sources

Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. [PDF]

, 2019
The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly ...
Bandyopadhyay, Guatam K, Cabrales, Pedro, Lee, Yun Sok, Riopel, Matthew   +3 more
core  

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [PDF]

, 2016
Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. Methods In this double-blind trial, we randomly assigned patients with type 2 diabetes
Bergenstal, RM, Brown-Frandsen, K, Buse, JB, Daniels, GH, Kristensen, P, LEADER Steering Committee on behalf of the LEADER Trial Investigators, Mann, JF, Marso, SP, Nauck, MA, Nissen, SE, Pocock, S, Poulter, NR, Ravn, LS, Steinberg, WM, Stockner, M, Zinman, B   +15 more
core   +1 more source